Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10312765" target="_blank" >RIV/00216208:11110/15:10312765 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/15:A1601FXG RIV/00843989:_____/15:E0104883 RIV/00064165:_____/15:10312765
Result on the web
<a href="http://dx.doi.org/10.1111/bjh.13582" target="_blank" >http://dx.doi.org/10.1111/bjh.13582</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/bjh.13582" target="_blank" >10.1111/bjh.13582</a>
Alternative languages
Result language
angličtina
Original language name
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up
Original language description
This follow-up extension of a randomised phase II study assessed differences in long-term outcomes between bortezomib-thalidomide-dexamethasone (VTD) and VTD-cyclophosphamide (VTDC) induction therapy in multiple myeloma. Newly diagnosed patients (n = 98)were randomised 1: 1 to intravenous bortezomib (1.3 mg/m(2); days 1, 4, 8, 11), thalidomide (100 mg; days 1-21), and dexamethasone (40 mg; days 1-4, 9-12), with/without cyclophosphamide (400 mg/m(2); days 1, 8), for four 21-day cycles before stem-cell mobilisation/transplantation. After a median follow-up of 64.8 months, median time-to-next therapy was 51.8 and 47.9 months with VTD and VTDC, respectively. Type of subsequent therapy was similar in both arms. After adjusting for asymmetric censoring, median time to progression was not significantly different between VTD and VTDC [35.7 vs. 34.5 months; Hazard ratio (HR) 1.26, 95% confidence interval: 0.76-2.09; P = 0.370]. Five-year survival was 69.1% and 65.3% with VTD and VTDC, respecti
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
British Journal of Haematology
ISSN
0007-1048
e-ISSN
—
Volume of the periodical
171
Issue of the periodical within the volume
3
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
344-354
UT code for WoS article
000363946100007
EID of the result in the Scopus database
2-s2.0-84944274779